TP-03 + TP-03 Vehicle
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Meibomian Gland Dysfunction
Conditions
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Trial Timeline
Aug 3, 2022 → May 18, 2023
NCT ID
NCT05454956About TP-03 + TP-03 Vehicle
TP-03 + TP-03 Vehicle is a phase 2 stage product being developed by Tarsus Pharmaceuticals for Meibomian Gland Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT05454956. Target conditions include Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation.
What happened to similar drugs?
0 of 1 similar drugs in Meibomian Gland Dysfunction were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05454956 | Phase 2 | Completed |
| NCT04784091 | Phase 3 | Completed |
Competing Products
3 competing products in Meibomian Gland Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vehicle of TP-03 | Tarsus Pharmaceuticals | Phase 2 | 33 |
| SHR8058 eye drops + saline eye drops. | Jiangsu Hengrui Medicine | Phase 3 | 40 |
| Azasite | Merck | Phase 2 | 27 |